TY - JOUR T1 - Pulmonary Hypertension JF - European Respiratory Review JO - EUROPEAN RESPIRATORY REVIEW SP - 193 LP - 194 VL - 18 IS - 113 AU - V. Cottin Y1 - 2009/09/01 UR - http://err.ersjournals.com/content/18/113/193.abstract N2 - Edited by M. Humbert and J.P. Lynch Published by Informa Healthcare UK Pages: 550. Price: £125. ISBN: 978‐1420094756 Pulmonary hypertension (PH) is an area of clinical medicine and medical science that is exemplary in many aspects, with tremendous progress having been made in a relatively short period of time. Identification of this condition was made possible in 1950 with the introduction of right heart catheterisation. The interest of the medical community really began in 1973 with the first international meeting dedicated to “primary” pulmonary hypertension, when the incidence of PH had notably increased due to the use of the anorexigen aminorex fumarate. Although idiopathic pulmonary arterial hypertension (PAH) is a rare condition, the global burden of PH as a whole is largely underestimated. In 2009, PH is no longer only a disease common in young females often related to the use of anorexigen, but may be encountered as a result of a growing list of conditions or risk factors. When present, PH has been proven to affect the long‐term prognosis of many chronic diseases, including chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. With progress in pathophysiology, diagnosis, classification, treatment, management and prognosis, pulmonary hypertension has been “adopted” by the medical community, and is no longer an orphan disorder. Given the amount of recently … ER -